Tracey Weiss, MPH


Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

August 25, 2021

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.